Crossmark

Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia

Crossref DOI link: https://doi.org/10.1016/j.htct.2023.06.001

Published Print: 2024-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Braga, Arthur Gomes Oliveira http://orcid.org/0000-0001-9223-9139
Barbosa Pagnano, Katia Borgia http://orcid.org/0000-0001-7975-0805
Campioni, Marina Dal'Bó Pelegrini http://orcid.org/0000-0001-5776-6435
Lopes, Ana Beatriz Pascoal http://orcid.org/0000-0002-4720-6669
Duarte, Gislaine Oliveira

Metze, Konradin http://orcid.org/0000-0003-0742-8846
Lorand-Metze, Irene http://orcid.org/0000-0002-6516-1265
Funding

Funding for this research was provided by:

CAPES (88882.434900/2019-01)

National Research Council

CNPq (305110/2018-7)
License Information

Text and Data Mining valid from 2024-07-01

Text and Data Mining valid from 2024-07-01

Version of Record valid from 2023-06-27
More Information

This article is maintained by: Elsevier

Article Title: Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2023.06.001

Content Type: article

Copyright: © 2023 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below